SynthesisStroke and vascular neurology2018
Efficacy and safety of intravenous recombinant tissue plasminogen activator in mild ischaemic stroke: a meta-analysis.
Synthesis in Stroke and vascular neurology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 7 syntheses or guidelines pooled it.
- Antiplatelet therapy versus intravenous thrombolysis for mild acute ischaemic stroke: a living systematic review and meta-analysis.Stroke and vascular neurology · 2025Pooled it
- Safety and efficacy of intravenous thrombolysis: a systematic review and meta-analysis of 93,057 minor stroke patients.BMC neurology · 2025Pooled it
- Intravenous alteplase in minor nondisabling ischemic stroke: A systematic review and meta-analysis.European stroke journal · 2024Pooled it
- Intravenous thrombolysis versus dual antiplatelet therapy for patients with acute minor ischaemic stroke: a systematic review and meta-analysis.Frontiers in pharmacology · 2024Pooled it
- Thrombolytic therapy for patients with acute ischemic stroke: systematic review and network meta-analysis of randomized trials.Frontiers in neurology · 2024Pooled it
- Efficacy and safety of intravenous thrombolysis versus standard medical management for minor stroke: a systematic review and meta-analysis of RCTs.Frontiers in neurologyPooled it
- Comparing Efficacy and Safety of Dual Antiplatelet Therapy versus Intravenous Thrombolytics in Acute Minor Ischemic Stroke: A Systematic Review and Meta-Analysis.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/HemostasisPooled it
- Onset to Treatment Time and Early Neurological Deterioration of Dual Antiplatelet Therapy Versus Alteplase in Minor Stroke.Journal of the American Heart Association · 2025Trial
- "Minor" stroke: not a minor, still open question.Journal of thrombosis and thrombolysis · 2020Trial
- Prevalence and outcomes of mild stroke patients undergoing reperfusion therapy: A meta-analysis and SAFE recommendations for optimal management.Journal of central nervous system disease · 2025Article
- Effects of intravenous rtPA in patients with minor stroke.Annals of medicine · 2024Article
- Combining Intravenous Thrombolysis and Dual Antiplatelet Treatment in Patients With Minor Ischemic Stroke: A Propensity Matched Analysis of the READAPT Study Cohort.Journal of the American Heart Association · 2024Observational
- Article
- IV Thrombolysis vs Early Dual Antiplatelet Therapy in Patients With Mild Noncardioembolic Ischemic Stroke.Neurology · 2023Article
- Outcomes in minor stroke patients treated with intravenous thrombolysis.CNS neuroscience & therapeutics · 2023Article
- Multidimensional Outcomes of IV Thrombolysis in Minor Ischemic Stroke: Motor, Psychocognitive, and Dependence.Neuropsychiatric disease and treatment · 2023Article
- The use of alteplase, although safe, does not offer clear clinical advantages when mild stroke is non-disabling.Frontiers in neurology · 2023Article
- SENP6 induces microglial polarization and neuroinflammation through de-SUMOylation of Annexin-A1 after cerebral ischaemia-reperfusion injury.Cell & bioscience · 2022Article
- Reasons and predictors of non-thrombolysis in patients with acute ischemic stroke admitted within 4.5 h.Acta neurologica Scandinavica · 2022Article
- Dual Antiplatelet Therapy in Patients With Minor Stroke Receiving Intravenous Thrombolysis.Frontiers in neurology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The benefits and safety of intravenous recombinant tissue plasminogen activator (IV-tPA) for patients with mild ischaemic stroke (MIS) are still unclear. The objective of this meta-analysis was to evaluate the efficacy and safety of IV-tPA as treatment for patients with MIS. We performed a systematic literature search across MEDLINE, Embase, Central, Global Health and Cumulative Index to Nursing and Allied Health Literature (CINAHL), from inception to 10 November 2016, to identify all related studies. Where possible, data were pooled for meta-analysis with odds ratio (OR) and corresponding 95% confidence interval (CI) using the fixed-effects model. MIS was defined as having National Institutes of Health Stroke Scale score of ≤6. We included seven studies with a total of 1591 patients based on the prespecified inclusion and exclusion criteria. The meta-analysis indicated a high odds of excellent functional outcome based on the modified Rankin Scale or Oxfordshire Handicap Score 0-1 (OR=1.43; 95% CI 1.14 to 1.79; P=0.002, I
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.